SCHEMBL4949867

SCHEMBL4949867

NC(=O)c1sc(NC(=O)[CH]CCc2ccccc2)nc1-c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTO1 P78417 2/20 0.49
CDC7 O00311 1/20 0.47
CCNE1 P24864 1/20 0.47
CDK2 P24941 1/20 0.47
DBF4 Q9UBU7 1/20 0.47
ADORA3 P0DMS8 4/20 0.46
ADORA2B P29275 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
HPGD P15428 2/20 0.46
KMT2A Q03164 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
ALDH1A1 P00352 3/20 0.46
ADORA2A P29274 4/20 0.45
ADORA1 P30542 4/20 0.45
MEN1 O00255 4/20 0.45
DHODH Q02127 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31423856 0.76 ADORA2B (0.74) CDC7CCNE1CDK2DBF4ADORA3
SCHEMBL4951232 0.76 ATAD2 (0.49) ADORA3NPC1RAB9AHPGDKMT2A
SCHEMBL5184585 0.74 GSTO1 (0.64) GSTO1ADORA3NPC1RAB9AHPGD
SCHEMBL4950587 0.72 XIAP (0.46) ADORA3ADORA2BNPC1RAB9AHPGD
SCHEMBL4949852 0.72 RAB9A (0.44) NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1
SCHEMBL14345629 0.71 ADORA2B (0.62) CDC7CCNE1CDK2DBF4ADORA2B
SCHEMBL4950581 0.70 NPC1 (0.40) ADORA3NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL31423857 0.70 RAB9A (0.63) CDC7CCNE1CDK2DBF4ADORA3
SCHEMBL31423858 0.70 TP53 (0.65) CDC7CCNE1CDK2DBF4ADORA3
SCHEMBL31423859 0.70 RAB9A (0.63) CDC7CCNE1CDK2DBF4ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080076741-A1 ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS REMPEX PHARMACEUTICALS, INC. 2008-03-27 US disclosed
US-20060003944-A1 Bacterial efflux pump inhibitors and methods of treating bacterial infections REMPEX PHARMACEUTICALS, INC. 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076741-A1 ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS ABCB1, ABCB11, SLC47A2 GSTO1 1169/4885CDC7 3848/4885CCNE1 2752/4885
US-20060003944-A1 Bacterial efflux pump inhibitors and methods of treating bacterial infections ABCB11, ABCB1, ABCC1 GSTO1 652/4885CDC7 3859/4885CCNE1 4073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.